Overview

The Repatriation Medical Authority Instrument No. 97 of 2010 amends the Veterans’ Entitlements Act 1986 and the Military Rehabilitation and Compensation Act 2004 by updating the Statement of Principles concerning ischaemic heart disease. This instrument was enacted to address the gap in existing legislation by introducing new factors related to acute cholinergic poisoning from exposure to an organophosphorus ester and providing new definitions for the terms. The Repatriation Medical Authority, acting under the authority granted by subsection 196B(3) and (8) of the Veterans’ Entitlements Act 1986, finalised this investigation after advertising in the Government Notices Gazette on 4 November 2009. This legislative instrument aims to ensure that veterans who have experienced acute cholinergic poisoning from exposure to organophosphorus esters receive appropriate recognition and support for related ischaemic heart disease claims.

Scope and Application

The Repatriation Medical Authority Instrument No. 97 of 2010 amends the Statement of Principles concerning ischaemic heart disease as outlined in Statement of Principles Instrument No. 90 of 2007, as amended by Instrument No. 44 of 2009, under the Veterans’ Entitlements Act 1986 and the Military Rehabilitation and Compensation Act 2004. This amendment applies to veterans and service personnel who have experienced ischaemic heart disease and adds new factors relating to episodes of acute cholinergic poisoning from exposure to an organophosphorus ester, as well as new definitions for these terms. The instrument is geographically applicable within Australia, impacting those who are eligible for benefits under the relevant acts. The amendment does not specify any exclusions or exemptions, but rather focuses on extending the scope of medical conditions considered under the act. The Authority’s determination is final and closes the investigation into ischaemic heart disease that was advertised in the Government Notices Gazette on 4 November 2009.

Key Provisions

The main operative sections of this legislation pertain to the amendment of Statement of Principles Instrument No. 90 of 2007 concerning ischaemic heart disease. This amendment, detailed in Statement of Principles Instrument No. 97 of 2010, introduces two new factors, 6(pa) and 6(ffa), that address the impact of an episode of acute cholinergic poisoning from exposure to an organophosphorus ester on ischaemic heart disease. Additionally, it includes new definitions for 'acute cholinergic poisoning' and 'an organophosphorus ester' in clause 9, enhancing the specificity and understanding of these terms within the legislative framework. This Instrument, determined under subsections 196B(3) and (8) of the Veterans’ Entitlements Act 1986, also outlines the date of effect for these amendments in accordance with subsection 12(1)(a) of the Legislative Instruments Act 2003. The Act imposes specific obligations on the Repatriation Medical Authority, requiring it to investigate and determine the inclusion of new factors and definitions in the context of ischaemic heart disease. This includes publicising its intention to investigate through advertisements in the Government Notices Gazette and circulating notices to relevant organisations and individuals. The Authority must also invite and consider submissions from the Repatriation Commission, organisations, persons with expertise in the field, and any other stakeholders identified in section 196E of the Veterans’ Entitlements Act 1986. Despite the invitation for submissions, no submissions were received for consideration during this investigation. Failure to comply with the obligations and requirements set out in this Act could lead to legal consequences, although the specific civil or criminal penalties for non-compliance are not detailed within the text. The primary focus of the Act is on ensuring that the amendments to the Statement of Principles Instrument accurately reflect the impact of acute cholinergic poisoning from exposure to an organophosphorus ester on ischaemic heart disease, thereby providing clearer guidance and potentially broader eligibility for veterans seeking benefits related to these conditions. The legislative amendments aim to enhance the fairness and accuracy of assessments and benefits related to ischaemic heart disease among veterans.